[Small cell lung cancer]. / Das kleinzellige Bronchialkarzinom.
Wien Klin Wochenschr
; 119(23-24): 697-710, 2007.
Article
en De
| MEDLINE
| ID: mdl-18157602
ABSTRACT
With about 20% of all lung cancers small cell lung cancer (SCLC) represents a major subset of this entity. Although therapeutic improvements did not receive as much attention as in non small cell lung cancer (NSCLC), many small steps of clinical progress have been achieved within the last 20 years. An optimal treatment should be based on an interdisciplinary treatment plan. The standard treatment in localized stages represents combined radiation and chemotherapy. Cisplatin and etoposide are in this concern considered as a gold standard. 3D-planned conformal radiotherapy should start as early as possible and should be applied concomitantly to chemotherapy and in certain cases even in a hyperfractionated treatment protocol. In very early stages surgical resection could be an option in selected cases. In advanced stages a platinum-based doublet offers high response rates. As already established in limited disease prophylactic cranial irradiation is now also indicated in extensive disease in case of any tumor remission. In the second line treatment and in patients with reduced performance status topotecan is recommended. Similar as in NSCLC pemetrexed might become an alternative treatment option in the second line setting. In the field of new targeted therapies bevacizumab achieved the most promising results. The present review highlights historical milestones and up-to-date trends in radiotherapy, chemotherapy and surgery. Furthermore, the role of experimental strategies and the management of certain special clinical situations are discussed.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Radioterapia
/
Carcinoma de Células Pequeñas
/
Quimioterapia
/
Neoplasias Pulmonares
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
De
Revista:
Wien Klin Wochenschr
Año:
2007
Tipo del documento:
Article